WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > AliveCor Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Fiercepharma | April 29, 2020
As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...
Pharmacy Market
Eirion Therapeutics, Inc. | September 09, 2021
Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion's exclusive botulinum active pharmaceutical ingredient (API) manufacturer. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and prima...
PharmaTimes | January 28, 2020
The NHS has announced new “expert rapid response teams” in order to help support older people to remain well at home and avoid hospital admissions. New plans outlined by the health service say that the teams will be able to be on hand within two hours, as part of the NHS’ Long Term Plan to support England’s ageing population and those with complex needs. Backed by £14 million of investment, local health service and council teams will begin the roll out of the servic...
prnewswire | August 29, 2023
Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE